Suppr超能文献

严重急性呼吸综合征冠状病毒 2 感染对哮喘患儿症状控制和肺功能的影响。

The Impact of SARS-CoV-2 Infection on Symptom Control and Lung Function in Children with Asthma.

机构信息

Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Division of Pulmonary Medicine.

出版信息

Ann Am Thorac Soc. 2023 Nov;20(11):1605-1613. doi: 10.1513/AnnalsATS.202302-117OC.

Abstract

Little is known about the long-term impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on children with asthma. To determine whether SARS-CoV-2 infection affects symptom control and lung function in children with asthma. Using data from clinical registries and the electronic health record, we conducted a prospective case-control study of children with asthma aged 6-21 years who had (cases) or did not have (control subjects) SARS-CoV-2 infection, comparing baseline and follow-up asthma symptom control and spirometry within an ∼18-month time frame and, for cases, within 18 months of acute coronavirus disease (COVID-19). A total of 171 cases had baseline and follow-up asthma symptom data, and 114 cases had baseline and follow-up spirometry measurements. There were no significant differences in asthma symptom control ( = 0.50), forced expiratory volume in 1 second ( = 0.47), forced vital capacity ( = 0.43), forced expiratory volume in 1 second/forced vital capacity ( = 0.43), or forced expiratory flow, midexpiratory phase ( = 0.62), after SARS-CoV-2 infection. Compared with control subjects (113 with symptom data and 237 with spirometry data), there were no significant differences in follow-up asthma symptom control or lung function. A similar proportion of cases and control subjects had poorer asthma symptom control (17.5% vs. 9.7%;  = 0.07) or worse lung function (29.0% vs. 32.5%;  = 0.50) at follow-up. Patients whose asthma control worsened after COVID-19 had a shorter time to follow-up (3.5 [1.5-7.5] vs. 6.1 [3.1-9.8] mo;  = 0.007) and were more likely to have presented with an asthma exacerbation during COVID-19 (46% vs. 26%;  = 0.04) than those without worse control. We found no significant differences in asthma symptom control or lung function in youth with asthma up to 18 months after acute COVID-19, suggesting that COVID-19 does not affect long-term asthma severity or control in the pediatric population.

摘要

目前对于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染对哮喘儿童的长期影响知之甚少。为了确定 SARS-CoV-2 感染是否会影响哮喘儿童的症状控制和肺功能,我们使用临床登记处和电子健康记录中的数据,对 6-21 岁患有 SARS-CoV-2 感染(病例)或未感染 SARS-CoV-2 感染(对照)的哮喘儿童进行了前瞻性病例对照研究,比较了约 18 个月的时间内哮喘症状控制和肺活量,并对病例进行了急性冠状病毒病(COVID-19)后 18 个月的比较。共有 171 例病例有基线和随访哮喘症状数据,114 例病例有基线和随访肺活量测量值。在 SARS-CoV-2 感染后,哮喘症状控制( = 0.50)、1 秒用力呼气量( = 0.47)、用力肺活量( = 0.43)、1 秒用力呼气量/用力肺活量( = 0.43)或用力呼气中期流量( = 0.62)均无显著差异。与对照组(113 例有症状数据和 237 例有肺活量数据)相比,随访时哮喘症状控制或肺功能无显著差异。病例和对照组中,有相似比例的患者在随访时哮喘症状控制较差(17.5%比 9.7%; = 0.07)或肺功能更差(29.0%比 32.5%; = 0.50)。COVID-19 后哮喘控制恶化的患者随访时间更短(3.5[1.5-7.5]比 6.1[3.1-9.8]月; = 0.007),且更有可能在 COVID-19 期间发生哮喘加重(46%比 26%; = 0.04),而非控制恶化的患者。我们发现,在急性 COVID-19 后长达 18 个月,哮喘儿童的哮喘症状控制或肺功能无显著差异,表明 COVID-19 不会影响儿科人群的长期哮喘严重程度或控制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59ef/10632927/264da95292b6/AnnalsATS.202302-117OCf1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验